Sandoz

Patients

Biosimilars & patient access independent of geographies or s...

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

News

A pregnant woman with her hands forming a heart shape over her bump, wearing a beige sweater

NICE recommends wider use of MS drug natalizumab via NHS

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.

Market Access

Inside Sandoz: How women leaders are driving sustainability ...

News

Sandoz launches first biosimilar Tysabri in US

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

R&D

Eloise McLennan interview with Peter Stenico

Reuters Pharma Europe 2024 – Peter Stenico

Pioneering access to biosimilars is crucial for strengthening health equity by providing affordable, life-changing therapies to patients worldwide.

News

Sandoz gets first FDA OK for denosumab biosimilars

Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US

Biosimilars & patient access independent of geographies or s...

NICE recommends wider use of MS drug natalizumab via NHS

Inside Sandoz: How women leaders are driving sustainability ...

Sandoz launches first biosimilar Tysabri in US

Reuters Pharma Europe 2024 – Peter Stenico

Sandoz gets first FDA OK for denosumab biosimilars

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

Discover a new era of healthcare panel engagement: Grounded ...

Sandoz

Editor's Picks